MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine

Hyung Ho Moon, Min Kyung Joo, Hyejung Mok, Minhyung Lee, Ki Chul Hwang, Sung Wan Kim, Ji Hoon Jeong, Donghoon Choi, Sun Hwa Kim

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) have attracted much attention in regenerative medicine owing to their apparent usefulness as multi-potent replacement cells. The potential of MSC therapy can be further improved by transforming MSCs with therapeutic genes that maximize the efficacy of gene therapy and their own therapeutic ability. Since most conventional transfection methodologies have shown marginal success in delivering exogenous genes into primary cultured cells, efficient gene transfer into primary MSCs is a prerequisite for the development of MSC-based gene therapy strategies to achieve repair and regeneration of damaged tissues. Herein, facially amphipathic bile acid-modified polyethyleneimine (BA-PEI) conjugates were synthesized and used to transfer hypoxia-inducible vascular endothelial growth factor gene (pHI-VEGF) in MSCs for the treatment of rat myocardial infarction. Under the optimized transfection conditions, the BA-PEI conjugates significantly increased the VEGF protein expression levels in rat MSCs, compared with traditional transfection methods such as Lipofectamine™ and branched-PEI (25kDa). Furthermore, the prepared pHI-VEGF-engineered MSCs (VEGF-MSCs) resulted in improved cell viability, particularly during severe hypoxic exposure invitro. The transplantation of MSCs genetically modified to overexpress VEGF by BA-PEI enhanced the capillary formation in the infarction region and eventually attenuated left ventricular remodeling after myocardial infarction in rats. This study demonstrates the applicability of the BA-PEI conjugates for the efficient transfection of therapeutic genes into MSCs and the feasibility of using the genetically engineered MSCs in regenerative medicine for myocardial infarction.

Original languageEnglish
Pages (from-to)1744-1754
Number of pages11
JournalBiomaterials
Volume35
Issue number5
DOIs
Publication statusPublished - 2014 Feb 1

Fingerprint

Polyethyleneimine
Gene therapy
Stem cells
Bile Acids and Salts
Mesenchymal Stromal Cells
Genetic Therapy
Vascular Endothelial Growth Factor A
Rats
Myocardial Infarction
Acids
Transfection
Genes
Regenerative Medicine
Mesenchymal Stem Cell Transplantation
Cells
Gene transfer
Ventricular Remodeling
Polyetherimides
Therapeutics
Cell- and Tissue-Based Therapy

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Moon, Hyung Ho ; Joo, Min Kyung ; Mok, Hyejung ; Lee, Minhyung ; Hwang, Ki Chul ; Kim, Sung Wan ; Jeong, Ji Hoon ; Choi, Donghoon ; Kim, Sun Hwa. / MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine. In: Biomaterials. 2014 ; Vol. 35, No. 5. pp. 1744-1754.
@article{e30f0698f5c14a8a85e2409fdb3b7863,
title = "MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine",
abstract = "Mesenchymal stem cells (MSCs) have attracted much attention in regenerative medicine owing to their apparent usefulness as multi-potent replacement cells. The potential of MSC therapy can be further improved by transforming MSCs with therapeutic genes that maximize the efficacy of gene therapy and their own therapeutic ability. Since most conventional transfection methodologies have shown marginal success in delivering exogenous genes into primary cultured cells, efficient gene transfer into primary MSCs is a prerequisite for the development of MSC-based gene therapy strategies to achieve repair and regeneration of damaged tissues. Herein, facially amphipathic bile acid-modified polyethyleneimine (BA-PEI) conjugates were synthesized and used to transfer hypoxia-inducible vascular endothelial growth factor gene (pHI-VEGF) in MSCs for the treatment of rat myocardial infarction. Under the optimized transfection conditions, the BA-PEI conjugates significantly increased the VEGF protein expression levels in rat MSCs, compared with traditional transfection methods such as Lipofectamine™ and branched-PEI (25kDa). Furthermore, the prepared pHI-VEGF-engineered MSCs (VEGF-MSCs) resulted in improved cell viability, particularly during severe hypoxic exposure invitro. The transplantation of MSCs genetically modified to overexpress VEGF by BA-PEI enhanced the capillary formation in the infarction region and eventually attenuated left ventricular remodeling after myocardial infarction in rats. This study demonstrates the applicability of the BA-PEI conjugates for the efficient transfection of therapeutic genes into MSCs and the feasibility of using the genetically engineered MSCs in regenerative medicine for myocardial infarction.",
author = "Moon, {Hyung Ho} and Joo, {Min Kyung} and Hyejung Mok and Minhyung Lee and Hwang, {Ki Chul} and Kim, {Sung Wan} and Jeong, {Ji Hoon} and Donghoon Choi and Kim, {Sun Hwa}",
year = "2014",
month = "2",
day = "1",
doi = "10.1016/j.biomaterials.2013.11.019",
language = "English",
volume = "35",
pages = "1744--1754",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "5",

}

MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine. / Moon, Hyung Ho; Joo, Min Kyung; Mok, Hyejung; Lee, Minhyung; Hwang, Ki Chul; Kim, Sung Wan; Jeong, Ji Hoon; Choi, Donghoon; Kim, Sun Hwa.

In: Biomaterials, Vol. 35, No. 5, 01.02.2014, p. 1744-1754.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine

AU - Moon, Hyung Ho

AU - Joo, Min Kyung

AU - Mok, Hyejung

AU - Lee, Minhyung

AU - Hwang, Ki Chul

AU - Kim, Sung Wan

AU - Jeong, Ji Hoon

AU - Choi, Donghoon

AU - Kim, Sun Hwa

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Mesenchymal stem cells (MSCs) have attracted much attention in regenerative medicine owing to their apparent usefulness as multi-potent replacement cells. The potential of MSC therapy can be further improved by transforming MSCs with therapeutic genes that maximize the efficacy of gene therapy and their own therapeutic ability. Since most conventional transfection methodologies have shown marginal success in delivering exogenous genes into primary cultured cells, efficient gene transfer into primary MSCs is a prerequisite for the development of MSC-based gene therapy strategies to achieve repair and regeneration of damaged tissues. Herein, facially amphipathic bile acid-modified polyethyleneimine (BA-PEI) conjugates were synthesized and used to transfer hypoxia-inducible vascular endothelial growth factor gene (pHI-VEGF) in MSCs for the treatment of rat myocardial infarction. Under the optimized transfection conditions, the BA-PEI conjugates significantly increased the VEGF protein expression levels in rat MSCs, compared with traditional transfection methods such as Lipofectamine™ and branched-PEI (25kDa). Furthermore, the prepared pHI-VEGF-engineered MSCs (VEGF-MSCs) resulted in improved cell viability, particularly during severe hypoxic exposure invitro. The transplantation of MSCs genetically modified to overexpress VEGF by BA-PEI enhanced the capillary formation in the infarction region and eventually attenuated left ventricular remodeling after myocardial infarction in rats. This study demonstrates the applicability of the BA-PEI conjugates for the efficient transfection of therapeutic genes into MSCs and the feasibility of using the genetically engineered MSCs in regenerative medicine for myocardial infarction.

AB - Mesenchymal stem cells (MSCs) have attracted much attention in regenerative medicine owing to their apparent usefulness as multi-potent replacement cells. The potential of MSC therapy can be further improved by transforming MSCs with therapeutic genes that maximize the efficacy of gene therapy and their own therapeutic ability. Since most conventional transfection methodologies have shown marginal success in delivering exogenous genes into primary cultured cells, efficient gene transfer into primary MSCs is a prerequisite for the development of MSC-based gene therapy strategies to achieve repair and regeneration of damaged tissues. Herein, facially amphipathic bile acid-modified polyethyleneimine (BA-PEI) conjugates were synthesized and used to transfer hypoxia-inducible vascular endothelial growth factor gene (pHI-VEGF) in MSCs for the treatment of rat myocardial infarction. Under the optimized transfection conditions, the BA-PEI conjugates significantly increased the VEGF protein expression levels in rat MSCs, compared with traditional transfection methods such as Lipofectamine™ and branched-PEI (25kDa). Furthermore, the prepared pHI-VEGF-engineered MSCs (VEGF-MSCs) resulted in improved cell viability, particularly during severe hypoxic exposure invitro. The transplantation of MSCs genetically modified to overexpress VEGF by BA-PEI enhanced the capillary formation in the infarction region and eventually attenuated left ventricular remodeling after myocardial infarction in rats. This study demonstrates the applicability of the BA-PEI conjugates for the efficient transfection of therapeutic genes into MSCs and the feasibility of using the genetically engineered MSCs in regenerative medicine for myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=84890154858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890154858&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2013.11.019

DO - 10.1016/j.biomaterials.2013.11.019

M3 - Article

C2 - 24280192

AN - SCOPUS:84890154858

VL - 35

SP - 1744

EP - 1754

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 5

ER -